Hangzhou Alltest Biotech Co., Ltd.

Shanghai Stock Exchange 688606.SS

Hangzhou Alltest Biotech Co., Ltd. Free Cash Flow Yield on January 14, 2025: -10.12%

Hangzhou Alltest Biotech Co., Ltd. Free Cash Flow Yield is -10.12% on January 14, 2025, a -3.89% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Hangzhou Alltest Biotech Co., Ltd. 52-week high Free Cash Flow Yield is -8.48% on April 26, 2024, which is 16.19% above the current Free Cash Flow Yield.
Hangzhou Alltest Biotech Co., Ltd. 52-week low Free Cash Flow Yield is -13.95% on July 04, 2024, which is -37.88% below the current Free Cash Flow Yield.
Hangzhou Alltest Biotech Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is -10.76%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 688606.SS

Hangzhou Alltest Biotech Co., Ltd.

CEO	Mr. Fei Gao
IPO Date	March 25, 2021
Location	China
Headquarters	#550, Yinhai Street
Employees	1,093
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and market of in vitro diagnostic reagents worldwide. It offers rapid diagnostic products, including women's health, infectious diseases, drugs, cancer, cardiovascular, and other five series of products. The company is based in Hangzhou, China.

Key trends

Past 5 years